News

New York City has ended their mpox outbreak after months of successful community outreach and vaccination campaigns.

The agency said it was revising the Emergency Use Authorizations (EUA) for Lagevrio and Paxlovid in order to protect public health.

University of Missouri investigators found people experiencing post-acute sequelae of COVID-19 (long COVID) are susceptible to developing 7 health defects in the year following infection.

A specific brand, EzriCare Artificial Tears, has been associated with multidrug resistant (MDR) Pseudomonas aeruginosa. In addition, FDA has sent a letter to companies making claims of prevention and treatment for mpox.

Patients treated with SER-109 reported a significant improvement in disease-specific health-related quality-of-life, regardless of their clinical outcome.

The declaration set for May is a wind-down to allow health care and patients the time needed to adjust for the emergency to be over.

This first-in-human, phase 1 vaccine trial produced a lasting immune response against Marburg virus.

The designation was based on positive top line data from the ConquerRSV phase 3 efficacy trial.

COVID-19 mortalities tend to be lowest in children, but the virus is still the #8 cause of death in children and young people 0-19 years old.

These diseases, exacerbated by poor water quality, sanitation, and health care access, are highlighted today.

The investigational therapy developed by Entasis is indicated for treatment of Acinetobacter baumannii.

Patients suffering from post-acute sequelae of COVID-19, or “long COVID,” had virus-specific T cells that were more than 100 times higher than patients who fully recovered from COVID-19 infection.

A new report tracking patients suggests that even those who return to work experience persistent symptoms.

In the latest Morbidity and Mortality Weekly Report, authors offer some strategies to avoid SARS-CoV-2 infection in this patient population as well as the US government changes course on COVID-19 vaccine policy.

Utopia Foods, Inc., issued a voluntary recall after their imported Chinese enoki mushrooms tested positive for 2 strains of Listeria monocytogenes involved in an outbreak.

The week's most-clicked COVID-19 stories included vaccine updates, new variants, and a pivotal FDA advisory committee vote.

Novavax will update its protein-based COVID-19 vaccine, but maintains the current vaccine is effective against current and future variants.

The agency would like to begin using individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

The federal agency does not want clinicians utilizing this neutralizing antibody as newer, circulating COVID-19 strains and efficacy against them is limited.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to move toward a unified strain composition for COVID-19 primary and booster vaccines.

In the CDC’s latest Morbidity and Mortality Weekly Report, investigators reported the Moderna and Pfizer-BioNTech updated vaccines helped prevent acute infection from the latest Omicron mutations.

The Pfizer-BioNTech COVID-19 vaccine was associated with rare instances of myo/pericarditis and acute kidney injury, according to a nationwide study in New Zealand that confirmed the safety profile of the vaccine.

Investigators identify a mechanism that’s vital to the progression of alcohol-related hepatitis, paving the way for new treatments.

Sky-high costs with little wiggle room to negotiate mean fidaxomicin remains underprescribed for recurrent C diff, despite favorable outcomes.

If approved on its March PDUFA date, rezafungin could be the first new Candida treatment option in over a decade.

The new guidance looks at preexposure and postexposure prophylaxis as well as treatment for COVID-19.

A recreation of a failed staph vaccine trial unveiled that previous exposure to S aureus made the vaccine candidate ineffective.

A new study demonstrated continuous neutralization after 3 doses.